ACG clinical guideline: Alcoholic liver disease

Ashwani K. Singal, Ramon Bataller, Joseph Ahn, Patrick S. Kamath, Vijay H. Shah

Research output: Contribution to journalReview article

  • 11 Citations

Abstract

Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.

LanguageEnglish (US)
Pages175-194
Number of pages20
JournalAmerican Journal of Gastroenterology
Volume113
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Alcoholic Liver Diseases
Alcoholic Hepatitis
Guidelines
Liver Diseases
Alcoholic Liver Cirrhosis
Alcohols
Alcohol Abstinence
Therapeutics
Mortality
Liver Failure
Fatty Liver
Disease Management
Jaundice
Documentation
Liver Transplantation
Disease Progression
Inpatients
Adrenal Cortex Hormones
Anti-Bacterial Agents
Survival

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S., & Shah, V. H. (2018). ACG clinical guideline: Alcoholic liver disease. American Journal of Gastroenterology, 113(2), 175-194. https://doi.org/10.1038/ajg.2017.469

ACG clinical guideline : Alcoholic liver disease. / Singal, Ashwani K.; Bataller, Ramon; Ahn, Joseph; Kamath, Patrick S.; Shah, Vijay H.

In: American Journal of Gastroenterology, Vol. 113, No. 2, 01.02.2018, p. 175-194.

Research output: Contribution to journalReview article

Singal, AK, Bataller, R, Ahn, J, Kamath, PS & Shah, VH 2018, 'ACG clinical guideline: Alcoholic liver disease' American Journal of Gastroenterology, vol. 113, no. 2, pp. 175-194. https://doi.org/10.1038/ajg.2017.469
Singal, Ashwani K. ; Bataller, Ramon ; Ahn, Joseph ; Kamath, Patrick S. ; Shah, Vijay H. / ACG clinical guideline : Alcoholic liver disease. In: American Journal of Gastroenterology. 2018 ; Vol. 113, No. 2. pp. 175-194.
@article{5081ff149ee44e68814714bb930c1c28,
title = "ACG clinical guideline: Alcoholic liver disease",
abstract = "Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50{\%} at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.",
author = "Singal, {Ashwani K.} and Ramon Bataller and Joseph Ahn and Kamath, {Patrick S.} and Shah, {Vijay H.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1038/ajg.2017.469",
language = "English (US)",
volume = "113",
pages = "175--194",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - ACG clinical guideline

T2 - American Journal of Gastroenterology

AU - Singal, Ashwani K.

AU - Bataller, Ramon

AU - Ahn, Joseph

AU - Kamath, Patrick S.

AU - Shah, Vijay H.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.

AB - Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.

UR - http://www.scopus.com/inward/record.url?scp=85042469472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042469472&partnerID=8YFLogxK

U2 - 10.1038/ajg.2017.469

DO - 10.1038/ajg.2017.469

M3 - Review article

VL - 113

SP - 175

EP - 194

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -